Abstract: BMS-986165 (Deucravacitinib) is a first-in-class, highly selective, oral allosteric inhibitor of tyrosine kinase 2 (TYK2). While initially approved for the treatment of moderate-to-severe plaque psoriasis, deucravacitinib has emerged as a highly promising targeted therapy for Systemic Lupus Erythematosus (SLE). By binding to the regulatory pseudokinase domain (JH2) of TYK2 rather than the conserved catalytic domain (JH1), deucravacitinib achieves unprecedented selectivity, effectively blocking the intracellular signaling of key pathogenic cytokines—namely interleukin (IL)-12, IL-23, and type I interferons (IFNs)—without the systemic toxicities associated with nonselective Janus kinase (JAK) inhibitors. Clinical evaluations, including the phase II PAISLEY trial, have demonstrated significant improvements in SLE disease activity indices, such as the SLE Responder Index (SRI-4) and the BILAG-based Composite Lupus Assessment (BICLA), alongside favorable safety profiles. This review synthesizes the pharmacological activity, molecular mechanism of action, structure-activity relationship, current limitations, and future perspectives of deucravacitinib in the context of SLE treatment.
1. Introduction
Systemic Lupus Erythematosus (SLE) is a complex, highly heterogeneous autoimmune disease characterized by a regulatory imbalance between intrinsic and adaptive immunity. This dysregulation leads to the production of autoantibodies, the formation of immune complexes, and subsequent multi-organ inflammatory damage [16]. The pathogenesis of SLE is heavily driven by dysregulated B-cell activation and overactive type I interferon (IFN-I) signaling [16].
Deucravacitinib (BMS-986165) is a novel, oral, small-molecule inhibitor of tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family [1]. Following its first global approval for the treatment of moderate-to-severe plaque psoriasis, deucravacitinib is currently undergoing extensive clinical development for multiple immune-mediated inflammatory diseases, including SLE, discoid lupus erythematosus (DLE), and cutaneous lupus erythematosus (CLE) [1][2].
2. Pharmacological Activity
Deucravacitinib has demonstrated robust clinical efficacy in SLE. In the 48-week, randomized, double-blind, placebo-controlled phase II PAISLEY study (NCT03252587), oral deucravacitinib showed significant therapeutic benefits in adults with active SLE [1]. At week 32, the proportion of patients achieving the primary endpoint—an SLE Responder Index [SRI(4)] response—was significantly higher in the deucravacitinib groups receiving 3 mg twice daily (58.2%) and 6 mg twice daily (49.5%) compared to placebo (34.4%) [1]. This SRI(4) response was sustained across all deucravacitinib groups up to week 48 [1].
Furthermore, deucravacitinib significantly outperformed placebo across multiple secondary endpoints, including the BILAG-based Composite Lupus Assessment (BICLA) response and the achievement of a Lupus Low Disease Activity State (LLDAS) [2][16]. Network meta-analyses highlight that deucravacitinib ranks highly for improving both SRI-4 and BICLA responses without significantly increasing the risk of adverse events [6][16].
Beyond clinical indices, deucravacitinib treatment significantly improved SLE-associated biomarkers, including anti-dsDNA antibody titers and complement components C3 and C4 [2]. In cutaneous manifestations, deucravacitinib achieved significantly higher odds of a CLASI-50 response (a 50% reduction in the Cutaneous Lupus Erythematosus Disease Area and Severity Index) compared to placebo, outperforming existing type I IFN-targeted therapies such as anifrolumab [2].
3. Molecular Mechanism of Action
TYK2 mediates the intracellular signaling of critical proinflammatory cytokines, including IL-12, IL-23, and type I IFNs, which are central to the pathogenesis of SLE [2][9]. Deucravacitinib acts as a highly potent and selective allosteric inhibitor of TYK2. It binds to the pseudokinase regulatory domain (JH2) of the enzyme, stabilizing an inhibitory interaction between the regulatory and catalytic domains, thereby locking the kinase in an inactive state [1][6].
By inhibiting TYK2, deucravacitinib blocks the downstream signaling of the IL-12/IL-23 and type I IFN pathways [6]. In ex vivo tests using whole blood from SLE patients, deucravacitinib dose-dependently decreased the expression of type I IFN-regulated genes (such as CXCL10, ISG20, and IFI27) that are typically overexpressed in SLE, providing almost complete inhibition at a dose of 12 mg twice daily [4]. Additionally, deucravacitinib strongly inhibits lymphopenia induced by IFN-alpha, a significant pathophysiological feature of SLE where IFN-alpha promotes the migration of lymphocytes into lymph nodes [6].
4. Structure-Activity Relationship (SAR)
The structural basis for deucravacitinib's efficacy and safety lies in its unique allosteric binding mechanism. Most traditional JAK inhibitors are orthosteric, impeding ATP binding at the highly conserved JH1 catalytic domain, which leads to off-target inhibition of other JAK family members (JAK1, JAK2, JAK3) [4][9]. In contrast, deucravacitinib specifically targets the JH2 pseudokinase domain, which is structurally distinct in TYK2 [4].
This structural selectivity translates to profound functional selectivity. In cell-based analyses, deucravacitinib is approximately 200 times more selective for TYK2 over JAK1/JAK3, and over 3,000 times more selective over JAK2 [6]. Consequently, deucravacitinib avoids the systemic toxicities commonly associated with nonselective JAK inhibitors, such as significant alterations in hematologic parameters, dyslipidemia, and thromboembolic events [4][9][15]. Pharmacokinetically, its major metabolite, BMT-153261, retains comparable potency to the parent drug and accounts for approximately 20% of systemic exposure [1].
5. Current Limitations
Despite promising phase II results, several limitations remain. While the PAISLEY trial demonstrated statistically significant improvements versus placebo, the overall effect size was moderate, and the trial did not specifically evaluate organ-specific endpoints [2]. Therefore, the extent to which deucravacitinib can reverse or improve individual organ involvement and long-term outcomes in SLE patients with established internal organ damage remains unclear [2].
Furthermore, current comparative efficacy data largely rely on indirect network meta-analyses; direct head-to-head clinical trials comparing deucravacitinib with other approved SLE biologics (e.g., belimumab or anifrolumab) are lacking [16]. Safety considerations also exist; deucravacitinib may increase the risk of mild-to-moderate infections, such as upper respiratory tract infections and nasopharyngitis [1]. It is currently not recommended for use in combination with other potent immunosuppressants or in patients with severe hepatic impairment (Child-Pugh C) [1].
6. Future Perspectives
The future of deucravacitinib in SLE hinges on the outcomes of ongoing large-scale phase III clinical trials, specifically POETYK SLE-1 (NCT05617677) and POETYK SLE-2 (NCT05620407), which aim to confirm its long-term efficacy and safety in broader SLE populations [2].
Additionally, deucravacitinib's dual modulation of the IL-23 and type I IFN pathways positions it as a highly attractive therapeutic option for complex overlap syndromes, such as patients presenting with both psoriasis and lupus-spectrum autoimmunity (e.g., SLE or CLE) [33]. Future research must also focus on biomarker-driven approaches to identify specific SLE patient subgroups—such as those with highly elevated IFN gene signatures—who are most likely to achieve optimal clinical benefits from selective TYK2 inhibition [16][33]. Further mechanistic studies clarifying the role of TYK2 in other cytokine pathways (e.g., IL-6, IL-10) will also be critical for maximizing its clinical utility across diverse autoimmune conditions [2].
